

RESEARCH ARTICLE

Open Access

Conditional disruption of interactions between $G\alpha_{i2}$ and regulator of G protein signaling (RGS) proteins protects the heart from ischemic injury

Sergio Parra¹, Xinyan Huang¹, Raelene A Charbeneau¹, Susan M Wade¹, Kuljeet Kaur¹, Boyd R Rorabaugh^{2*} and Richard R Neubig^{3*}

Abstract

Background: Regulator of G protein signaling (RGS) proteins suppress G protein coupled receptor signaling by catalyzing the hydrolysis of G α -bound guanine nucleotide triphosphate. Transgenic mice in which RGS-mediated regulation of $G\alpha_{i2}$ is lost (RGS insensitive $G\alpha_{i2}^{G184S}$) exhibit beneficial (protection against ischemic injury) and detrimental (enhanced fibrosis) cardiac phenotypes. This mouse model has revealed the physiological significance of RGS/ $G\alpha_{i2}$ interactions. Previous studies of the $G\alpha_{i2}^{G184S}$ mutation used mice that express this mutant protein throughout their lives. Thus, it is unclear whether these phenotypes result from chronic or acute $G\alpha_{i2}^{G184S}$ expression. We addressed this issue by developing mice that conditionally express $G\alpha_{i2}^{G184S}$.

Methods: Mice that conditionally express RGS insensitive $G\alpha_{i2}^{G184S}$ were generated using a floxed minigene strategy. Conditional expression of $G\alpha_{i2}^{G184S}$ was characterized by reverse transcription polymerase chain reaction and by enhancement of agonist-induced inhibition of cAMP production in isolated cardiac fibroblasts. The impact of conditional RGS insensitive $G\alpha_{i2}^{G184S}$ expression on ischemic injury was assessed by measuring contractile recovery and infarct sizes in isolated hearts subjected to 30 min ischemia and 2 hours reperfusion.

Results: We demonstrate tamoxifen-dependent expression of $G\alpha_{i2}^{G184S}$, enhanced inhibition of cAMP production, and cardioprotection from ischemic injury in hearts conditionally expressing $G\alpha_{i2}^{G184S}$. Thus the cardioprotective phenotype previously reported in mice expressing $G\alpha_{i2}^{G184S}$ does not require embryonic or chronic $G\alpha_{i2}^{G184S}$ expression. Rather, cardioprotection occurs following acute (days rather than months) expression of $G\alpha_{i2}^{G184S}$.

Conclusions: These data suggest that RGS proteins might provide new therapeutic targets to protect the heart from ischemic injury. We anticipate that this model will be valuable for understanding the time course (chronic versus acute) and mechanisms of other phenotypic changes that occur following disruption of interactions between $G\alpha_{i2}$ and RGS proteins.

Keywords: G protein coupled receptors, Ischemia-reperfusion, Cre-LoxP, Mutation, cAMP inhibition, Regulator of G protein signaling, RGS

* Correspondence: b-rorabaugh@onu.edu; rneubig@msu.edu

²Department of Pharmaceutical and Biomedical Sciences, Ohio Northern University College of Pharmacy, Ada, OH 45810, USA

³Department of Pharmacology and Toxicology, B440 Life Sciences, Michigan State University, 1355 Bogue St, East Lansing, MI 48824, USA

Full list of author information is available at the end of the article

Background

G protein coupled receptor signaling is mediated by four major families of G proteins (G_{α_s} , $G_{\alpha_{i/o}}$, G_{α_q} , and $G_{\alpha_{12}}$). G_{α_i} coupled receptors play important roles in regulating inflammation, cardiovascular function, endocrine signaling, drug abuse, and anxiety/depression – related behaviors [1-5]. Three different G_{α_i} - isoforms ($G_{\alpha_{i1}}$, $G_{\alpha_{i2}}$, $G_{\alpha_{i3}}$) have been cloned and characterized. $G_{\alpha_{i/o}}$ -coupled responses can be distinguished from responses mediated by other families of G proteins by their sensitivity to pertussis toxin, but the *in vivo* roles of individual $G_{\alpha_{i/o}}$ isoforms remain obscure.

Signaling through G_{α_i} is suppressed by regulator of G protein signaling (RGS) proteins which terminate G_{α_i} signaling by accelerating the hydrolysis of G_{α} -bound guanine nucleotide triphosphate (GTP) [6,7]. More than 20 different RGS proteins have been identified. However identifying the physiological roles of individual RGS proteins through selective pharmacological inhibition is not yet possible. Knockout mouse models in which individual RGS proteins have been genetically deleted have been useful in identifying the functions of some RGS proteins, but this approach is complicated by the potential for compensation of the lost RGS protein by other RGS proteins that may have redundant functions. Consequently, we have exploited a mutation in $G_{\alpha_{i2}}$ ($G_{\alpha_{i2}}^{G184S}$) that blocks RGS binding and activity [8]. This allows us to define the functions of this individual G_{α_i} -isoform and to explore the physiological roles of interactions between $G_{\alpha_{i2}}$ and endogenous RGS proteins [8,9]. Knock-in mice expressing $G_{\alpha_{i2}}^{G184S}$ show enhanced receptor-dependent signaling through $G_{\alpha_{i2}}$ [8,9], and they exhibit a number of interesting cardiac phenotype changes including enhanced carbachol-induced bradycardia, enhanced isoproterenol-induced cardiac fibrosis, and premature death in a dilated cardiomyopathy model [8-12]. Hearts from both homozygous and heterozygous $G_{\alpha_{i2}}^{G184S}$ mutant mice also exhibit smaller infarcts and better recovery of cardiac contractile function following an ischemic insult [13]. Genetic disruption of interactions between $G_{\alpha_{i2}}$ and endogenous RGS proteins also produces several noncardiac phenotypic changes including antidepressant-like behavior [5], resistance to high fat diet-induced weight gain, decreased body fat, and protection from the development of insulin resistance [14].

One limitation of this transgenic model is that the $G_{\alpha_{i2}}^{G184S}$ mutation is chronically expressed throughout the prenatal and postnatal life of the animal. Thus, it is unclear whether the phenotypes that have been reported result from changes during embryological development and whether the phenotypes require chronic or only acute disruption of interactions between $G_{\alpha_{i2}}$ and endogenous RGS proteins. In the present study, we addressed this issue by creating a conditional knock-in mouse model that

conditionally expresses RGS insensitive $G_{\alpha_{i2}}^{G184S}$. This study focused on the ability of acute $G_{\alpha_{i2}}^{G184S}$ expression to protect the heart from ischemic injury.


Methods

Gene targeting

All protocols and procedures were approved by the University Committee on Use and Care of Animals at the University of Michigan and by the Animal Care and Use Committee of Ohio Northern University. Experimental procedures and animal husbandry were conducted in accordance with NIH guidelines. Animals were housed in a specific pathogen free facility with a 12 hour: 12 hour light: dark cycle and free access to food and water. Mice expressing RGS-insensitive $G_{\alpha_{i2}}^{G184S}$ were generated by a “floxed minigene” strategy [15,16]. The targeting construct to create the conditional knock-in of the G184S mutation at $G_{\alpha_{i2}}$ (Figure 1A) was generated from a 129 BAC library in a manner similar to that previously described for the conventional $G_{\alpha_{i2}}^{G184S}$ knock-in mutant mice [11]. Elements included: a 6.4 kb 5' homology arm containing the endogenous *Gnai2* sequence encompassing exons 2 to 4, a minigene version of the wild type *Gnai2* gene composed of the fused exons 5 to 8, intron 8 and exon 9 (this *Gnai2* wild-type minigene was flanked with *loxP* sites allowing its deletion under the action of the Cre recombinase), the mutated exon 5 containing the G184S mutation (GGGC to TAGT mutation in position 85 in exon 5), a neo selection cassette flanked with FRT sites allowing its deletion under the Flp recombinase action, and a 2.4 kb 3' homology arm containing the endogenous *Gnai2* sequence encompassing exons 6 to 9 and sequence located downstream of the gene. In addition, *AflII* and *SacI* restriction sites were inserted in the 5' homology arm at the *BstEII* site between Exon 4 and the 5' *loxP* site to be used for Southern blot analysis of the targeted ES cells. A Thymidine Kinase (TK) negative selection marker was inserted upstream of the 5' homology arm. ES cells (5×10^6 cells - SV129 strain) were electroporated (GenOway; Lyon, France) with 40 μ g of linearized plasmid and selection started 48 hours later with 200 μ g/ml of G418 followed by selection in GANIX to enhance the likelihood of homologous recombination. Targeted cells were identified by 3' genomic PCR. Of the 23 positive clones, five also showed the appropriate presence of the *AflII/SacI* restriction site on 5' PCR. All five were confirmed by 5' and 3' Southern Blot analysis (13.0 kb *EcoNI* fragment and 11.5 kb *AflII* fragment, respectively) (GenOway; Lyon, France).

Mouse generation

Three independent embryonic stem (ES) cell lines with normal karyotype were used for blastocyst injection into C57BL/6J host blastocysts. Highly chimeric males were bred to C57BL/6J female mice and F1 agouti offspring



mice were genotyped by PCR and Southern blot hybridization to validate germline transmission (GenOway; Lyon, France). To delete the FRT-flanked neo gene, offspring showing the presence of the Gα₁₂^{+/fl-neo-G184S} allele by genomic PCR were crossed against beta-actin FLPe mice (from the University of Michigan Transgenic Animal Model Core). Litters from this cross were analyzed for the

presence of the FLP transgene as well as Gα₁₂ genotypes by genomic PCR. FLP/Gα₁₂^{+/fl-G184S} mice lacking the neo cassette were backcrossed onto the C57BL/6J strain to eliminate the FLPe gene. To generate whole-body Gα₁₂^{G184S} conditional knock-in mice, transgenic mice carrying the tamoxifen-sensitive, Cre-ER^{T2} gene driven by the ROSA26 promoter (The Jackson Laboratory; Bar

Harbor, ME) were bred with $G\alpha_{i2}^{fl-G184S/fl-G184S}$ mice. All mice used in this study have been backcrossed for five generations onto the C57BL/6J strain. They were between 8 – 20 weeks old and the number for each experiment is indicated in the figure legends. Animals were maintained in a specific pathogen-free facility with a 12-h light/dark cycle and fed standard laboratory chow and water ad libitum.

Genotyping

Genomic DNA was isolated from mouse tail using the HotSHOT method [17] and analyzed in a single PCR reaction using two forward primers A and C (GAGCCCA TGTTTCTTAAAGAAGCAAGGATA and TCCCACAC CTTAGTGCCACACCT, respectively) and reverse primer B (TGAGGACATGCCTTCCCAACACAAT), which amplify the $G\alpha_{i2}^{+}$ (492-bp) and $G\alpha_{i2}^{fl-G184S}$ (745-bp) alleles, respectively.

Tamoxifen preparation and treatment

Tamoxifen (Sigma, T5648) was prepared in peanut oil (Sigma, P2144) containing 10% ethanol at a concentration of 60 mg/ml [16]. Daily doses of 50 mg/kg over five days were given by intraperitoneal injection to induce recombination. Control mice were treated with vehicle (90% peanut oil/10% ethanol) alone.

Blood and tissue collection

Blood was withdrawn from the saphenous vein into dipotassium ethylenediamine tetraacetic acid -coated microtubes before the first and 72 hours after the last dose of tamoxifen and then stored at -80°C until processing for analysis. Mice were euthanized by pentobarbital injection and tissues were quickly removed, snap-frozen in liquid nitrogen, and stored at -80°C until analysis.

Recombination assessment

Qualitative assessment for recombination, before and after tamoxifen treatment, was performed by polymerase chain reaction (PCR) using genomic DNA isolated from whole blood and tissue samples from genotyped mice carrying one copy of the ROSA Cre-ER^{T2} gene and the indicated $G\alpha_{i2}$ alleles ($G\alpha_{i2}^{+/+}$ or $G\alpha_{i2}^{G184S}$ was amplified by using forward primer A and reverse primer B described above. This PCR reaction generates a 659-bp band only after Cre recombination. PCR reactions for testing genotype and recombination were carried out under the following conditions: 95°C for 5 min, 35 cycles at 95°C , and 64.5°C each for 30 s, followed by extension at 72°C for 1 min and final extension at 72°C for 2 min.

Western blotting

Tissues were dissected and homogenized in a Bullet Blender homogenizer (Next Advance; Averill Park, NY)

with RIPA buffer containing protease inhibitors (20 mM Tris-HCl, pH7.4, 150 mM NaCl, 1 mM EDTA, 1 mM β -glycerophosphate, 1% Triton X-100, 0.1% SDS, Complete protease inhibitor cocktail (Roche; Pleasanton, CA). Protein concentrations were measured using the BCA Protein Assay kit (Thermo Fisher Scientific; Rockford, IL). Eighty micrograms of protein were separated on a denaturing 12% SDS-PAGE gel and transferred to PVDF membrane. The membranes were washed, blocked (5% milk in PBS-T), and incubated in the appropriate antibodies overnight at 4°C . Antibodies for Western blot analysis: rabbit anti- $G\alpha_{i2}$ (a gift from Dr. Susanne Mumby, University of Texas Southwestern Medical Center) at a dilution of 1:1000 and mouse anti-GAPDH (Cell Signaling Technology, Danvers, MA), as loading control, at a dilution of 1:5000. Secondary antibodies were horseradish peroxidase conjugated. Visualization of the protein bands was done using the Super Signal West Pico chemiluminescent substrate (Thermo Fisher Scientific, Rockford, IL). Films were scanned and quantified using Image J software (NIH, Bethesda, MD). All samples were normalized with GAPDH as a loading control and the amount of $G\alpha_{i2}$ protein in wild type tissue was set to 100%.

Allele ratio conversion

RNA was isolated from whole blood, heart, brain, and kidney using a commercial kit (Qiagen, Valencia, CA), and reverse transcription was carried out using Reverse Transcription reagents (Applied Biosystems). PCR was performed using a set of primers that amplify a 442-base pair segment of $G\alpha_{i2}$ cDNA including both wildtype and $G\alpha_{i2}^{G184S}$. The primers used were CCAGCGTGCGGAT GATGCC and GATGAGGAGATGAACCGCATGCAT. The cDNA PCR products obtained for each sample were purified (Qiagen, Valencia, CA), and directly sequenced on an ABI 3730XL using the forward primer used for amplification of $G\alpha_{i2}$ in PCR. The allelic expression ratio of mutant $G\alpha_{i2}^{G184S}$ to wildtype $G\alpha_{i2}$ in mice was determined from the chromatogram peak heights of the bases differentiating between the $G\alpha_{i2}^{G184S}$ mutant and wildtype $G\alpha_{i2}$ alleles. Peak heights were determined using Image J software and mutant allele expression was calculated using the formula: % mutant allele expression = $(T + A + T\text{-peak heights}) / ((T + A + T\text{-peak heights}) + (G + G + C\text{-peak heights})) \times 100$. If any of the peaks of the mutant or the wild type sequence were not detected in the chromatogram the sample was considered 100% wild type or 100% mutant, respectively.

Adult cardiac fibroblast culture

Adult cardiac fibroblasts (ACF) were isolated from mice as previously described [12,18]. Hearts were quickly isolated, placed in ice-cold perfusion buffer, and then perfused via an aortic cannula for 4 min with calcium-free

perfusion buffer (NaCl, 113 mM; KCl, 4.7 mM; MgSO₄·7H₂O, 1.2 mM; Na₂HPO₄, 0.6 mM; KH₂PO₄, 0.6 mM; phenol red, 0.032 mM; HEPES, 10 mM; NaHCO₃, 12 mM; KHCO₃, 10 mM; taurine, 30 mM; glucose, 5.5 mM; and butanedione monoxime, 10 mM, pH 7.46). Hearts were then perfused for 8 min with the same buffer containing 0.5 mg/ml collagenase II (Worthington Biochemicals, Lakewood) and 1.25 μM CaCl₂. Hearts were removed from the apparatus and the ventricles were suspended in perfusion buffer with collagenase and 1.25 μM CaCl₂. The tissue was disrupted with fine forceps and by gentle pipetting. Cells were transferred to buffer containing 1.25 μM CaCl₂ and 10% serum to stop the digestion. Samples were centrifuged at 180×g for 1 min to remove debris and myocytes. The remaining suspended fibroblasts were centrifuged at 300 × g for 10 min, then resuspended in phosphate buffered saline, centrifuged again, the supernatant was discarded, and the final cell pellet was resuspended in Dulbecco's modified Eagle's medium supplemented with 1% penicillin/streptomycin, insulin/transferrin/selenium (ITS from Sigma) 1X, and 10% fetal bovine serum.

cAMP production in adult cardiac fibroblasts

The effect of lysophosphatidic acid (LPA) on 3',5' cyclic adenosine monophosphate (cAMP) production in ACF was determined in 384-well plates using the Lance Ultra cAMP kit (PerkinElmer; Waltham, MA). Briefly, ACF (passage 2) were added at 1,000 cells per well and cAMP accumulation was initiated by adding stimulation buffer containing 0.5 mM isobutyl-1-methylxanthine and 10 μM forskolin with the indicated concentrations of LPA. After 30 min at room temperature, the reaction was stopped by lysing the cells using the buffer supplied with the PerkinElmer kit. Time-resolved fluorescence was measured with a Synergy 2 (BioTek; Winooski, VT) microplate reader.

Langendorff isolated heart preparation and infarct size measurement

Mice were treated with tamoxifen or vehicle for 5 days as described above. Fourteen days after the first injection, mice were anesthetized and heparinized by a single injection containing pentobarbital (100 mg/kg) and heparin (150 mg/kg). Hearts were immediately excised and cannulated while bathed in ice-cold Krebs solution. Krebs solution was perfused through the aortic cannula at a constant pressure of 75 mmHg. Hearts were subjected to 30 minutes of ischemia and 2 hours reperfusion as previously described [13]. Contractile function of the left ventricle was continuously measured using an intraventricular balloon and infarct size was measured by triphenyltetrazolium chloride staining as described previously [13].

Statistical analyses

Data were analyzed using one-way or two-way analysis of variance, followed by a Bonferroni's post test or a Tukey's post test when appropriate. GraphPad Prism version 4.0 (GraphPad Software, San Diego, CA) was used for statistical analysis.

Results

To implement a conditional knock-in strategy, a replacement-type minigene targeting vector was used to modify the *Gnai2* gene as depicted in Figure 1A-C. This construct was designed to (1) flank an exon 5 through 9 minigene with *loxP* recombination recognition sites, (2) insert a neomycin selection cassette that was flanked by FRT recombination sites downstream of the floxed wild type $G\alpha_{i2}$ coding and regulatory sequences, and (3) replace the wildtype genomic exon 5 with the G184S mutant version followed by the remainder of the wildtype $G\alpha_{i2}$ sequence in the normal genomic context. Because of size constraints on the cloning vector used to create the targeting construct, exons 5 through 8 were fused and introns 5-7 were deleted. Intron 8 and non-coding exon 9 were retained due to the presence of regulatory elements. The knock-in mutation was introduced into the genomic exon 5 to change the codon for glycine 184 to serine (Figure 1A). Following electroporation of the targeting construct into embryonic stem cells, G418-resistant ES cell clones were screened for gene targeting by PCR and confirmed by Southern blot analysis. Blots were hybridized to 5' and 3' probes. After genomic DNA digestion with EcoNI, the 5' probe hybridized with a 13.0 kb fragment generated from a recombinant $G\alpha_{i2}^{G184S}$ allele (Figure 1D). This was confirmed by blotting with a 3' probe after genomic DNA digestion with AflIII. This probe hybridized to a 7.9 kb fragment from the wild type $G\alpha_{i2}$ allele and an 11.5 kb fragment from a $G\alpha_{i2}^{G184S}$ allele (Figure 1E). One ES cell clone was not targeted (lane 5) and four clones were correctly targeted (lanes 1 to 4). Three targeted ES cell clones with normal karyotype were used to produce germline-competent chimeric mice using standard techniques. After FLP recombinase crosses, mice that were heterozygous for the targeted locus without the neomycin cassette ($fl-G184S$ allele) were subsequently backcrossed with C57BL/6J mice to eliminate the beta-actin FLP transgene. Figure 2A shows representative results from the PCR screening used to select mice with the desired genotype.

To demonstrate a global, time-dependent, and Cre-mediated conversion of the conditional allele ($fl-G184S$) to the RGS insensitive allele ($G184S$), we crossed mice that were homozygous for the $fl-G184S$ allele ($G\alpha_{i2}^{fl-G184S/fl-G184S}$) mice with a tamoxifen-dependent Cre general deleter mouse line [19-21]. This line expresses a tamoxifen-sensitive Cre (Cre-ER^{T2}) from the ROSA26 locus




Figure 2 Representative agarose gel images assessing genotypes and recombination in mice. **A** PCR genotyping was done simultaneously using three primers A, B, and C from Figure 1. A 492-bp band represents the wild-type *Gnai2* allele and the 745-bp band represents the *Gnai2* fl-G184S conditional allele after removal of the *neo* cassette. **B** Genomic DNA extracted from blood was amplified before and after tamoxifen treatment. Lanes 1 and 2 were from Cre negative $G\alpha_{12}^{fl-G184S/fl-G184S}$ mice while lanes 3-6 were from Cre-ER^{T2}, $G\alpha_{12}^{fl-G184S/fl-G184S}$ mice. Tamoxifen-induced recombination was evaluated using primers A and B and confirms the in vivo conversion to the *G184S allele for expression of the RGS-insensitive $G\alpha_{12}$. The 659-bp band was exclusively generated after tamoxifen treatment (Tam). The non-recombined fl-G184S allele is not detected due to the large size of the PCR product (3189-bp).

(Figure 1C). When tamoxifen is administered, its metabolite 4-OH tamoxifen binds to the Cre-ER^{T2} which translocates to the nucleus facilitating recombination of genomic *loxP* sites. As shown in Figure 2B, this removes the E5-9 minigene and positions mutant Exon 5 (E5*) in the normal *Gnai2* genomic context to express the mutant $G\alpha_{12}^{G184S}$ protein. $G\alpha_{12}^{fl-G184S/fl-G184S}$ and Cre-ER^{T2}/ $G\alpha_{12}^{fl-G184S/fl-G184S}$ mice are viable and do not show any gross developmental abnormalities.

Reverse transcription-polymerase chain reaction (RT-PCR) analysis was used to amplify a 442-bp cDNA product expressed from the *Gnai2* gene to assess the ratio of mutant to wildtype $G\alpha_{12}$ RNA expression. Only the Cre-ER^{T2}/ $G\alpha_{12}^{+/-fl-G184S}$, or Cre-ER^{T2}/ $G\alpha_{12}^{fl-G184S/fl-G184S}$ mice express mutant mRNA after tamoxifen treatment. $G\alpha_{12}$ -specific PCR products from each genotype were sequenced (Figure 3A). This analysis confirmed that the $G\alpha_{12}$ cDNA sequence from $G\alpha_{12}^{fl-G184S/fl-G184S}$ mice prior to tamoxifen treatment was identical to the previously published mouse cDNA sequence [22,23]. In contrast, the $G\alpha_{12}$ cDNA sequence from Cre-ER^{T2}/ $G\alpha_{12}^{+/-fl-G184S}$, or Cre-ER^{T2}/ $G\alpha_{12}^{fl-G184S/fl-G184S}$ mice revealed the nucleotide

changes that were introduced to change the codon for glycine at 184 to serine. Peak heights from the chromatograms were used to quantify the relative amount of mutant mRNA expression in several tissues [24]. In mice that were homozygous for fl-G184S ($G\alpha_{12}^{fl-G184S/fl-G184S}$), we found 60 – 100% conversion to the mutant sequence in most tissues evaluated (Figure 3B). As expected, heterozygous animals ($G\alpha_{12}^{+/-fl-G184S}$) exhibited lower rates of conversion because they retained one copy of the wildtype allele. The lack of conversion in brain was presumably due to lack of Cre-ER^{T2} expression in post-mitotic neurons, and low brain penetration by tamoxifen [20].

Surprisingly, $G\alpha_{12}$ protein expression levels were significantly reduced in several organs (heart, brain, and kidney) isolated from $G\alpha_{12}^{fl-G184S/fl-G184S}$ and Cre-ER^{T2}/ $G\alpha_{12}^{fl-G184S/fl-G184S}$ mice compared to $G\alpha_{12}^{+/+}$ control animals that do not express Cre or the $G\alpha_{12}^{G184S}$ mutation (Figure 4). We also assessed whether there were compensatory changes in other G proteins in heart ventricles. We found no detectable levels of $G\alpha_o$, $G\alpha_{i1}$, or $G\alpha_{i3}$ in wildtype ventricles nor were they present in $G\alpha_{12}^{fl-G184S/fl-G184S}$ or Cre-ER^{T2}/ $G\alpha_{12}^{fl-G184S/fl-G184S}$ mice.





Figure 3 Efficiency and genotype specificity of Cre-induced mutant allele mRNA conversion (MAC) in tissues after tamoxifen treatment in $G\alpha_{12}^{fl-G184S}$ mice. **A** Representative chromatograms of sequenced PCR products from mRNA purified from hearts of tamoxifen-treated mice (50 mg/kg i.p. on five consecutive days). Mice lacking Cre ($Cre-ER^{T2(-)}$) showed no evidence of the TAGT sequence expected for G184S mutant mRNA (top chromatogram). For mice expressing Cre ($Cre-ER^{T2(+)}$), the percentage conversion to the mutated sequence (% MAC) was higher in mice that were homozygous for the G184S mutation ($G\alpha_{12}^{fl-G184S/fl-G184S}$, lower chromatogram) than in heterozygous ($G\alpha_{12}^{+/fl-G184S}$, middle chromatogram) animals. **B** The extent of recombination was higher in blood and liver than in other tissues with heart showing approximately 80% MAC in homozygotes. Values are expressed as the mean (\pm SE, $n = 3$) of the percentage of the mutated allele determined from the added peak heights of the three changed bases (see Methods).

$G\alpha_{12}^{fl-G184S/fl-G184S}$ ventricles either before or after tamoxifen treatment (data not shown). This is consistent with previous reports that $G\alpha_{12}$ is a predominant $G\alpha_i$ isoform in the myocardium [25,26].

We previously demonstrated that embryonic fibroblasts from conventional (i.e. non-conditional) $G\alpha_{12}^{G184S}$ knock-in mice have enhanced activity in several biochemical and physiological measures of the $G\alpha_i$ signaling pathway [8]. Thus, we investigated the functional consequences of conditional $G\alpha_{12}^{G184S}$ expression at the cellular level in a cAMP inhibition assay. Adult cardiac fibroblasts from mice treated with tamoxifen (which developed ~90% mutant allele expression, data not shown) were isolated and cultured. cAMP production in these cells was measured following exposure to forskolin (10 μ M) and increasing concentrations of lysophosphatidic acid (LPA). Data were compared by two-way ANOVA with genotype and LPA concentration as variables. A significant effect of genotype ($P < 0.05$) in the inhibition of cAMP production was observed. Bonferroni's post test revealed that ACF from the conditional knock-in mice ($Cre-ER^{T2}/G\alpha_{12}$) had significantly ($P < 0.05$) augmented inhibition of cAMP production with the highest concentration of LPA compared to cells from $G\alpha_{12}^{fl-G184S/fl-G184S}$ mice that do not convert to the G184S mutation (Figure 5). These data are consistent with our previous finding that LPA-induced inhibition of adenylate cyclase activity is enhanced in embryonic fibroblasts in the nonconditional $G\alpha_{12}^{G184S}$ model [13], and they provide evidence that agonist-induced $G\alpha_{12}$ signaling is enhanced in cardiac fibroblasts that conditionally express the $G\alpha_{12}^{G184S}$ allele.

We previously demonstrated that the conventional $G\alpha_{12}^{G184S}$ mutant mice (both heterozygotes and homozygotes) are resistant to ischemia-reperfusion injury [13]. However, it was unclear whether this phenotype resulted from $G\alpha_{12}^{G184S}$ expression during embryonic development or whether the cardioprotective phenotype requires chronic or acute $G\alpha_{12}^{G184S}$ expression. In the present study, we found that ischemia-induced infarct size was significantly decreased in tamoxifen-treated $Cre-ER^{T2}/G\alpha_{12}^{fl-G184S/fl-G184S}$ compared to both vehicle-treated $Cre-ER^{T2}/G\alpha_{12}^{fl-G184S/fl-G184S}$ hearts and tamoxifen-treated $G\alpha_{12}^{fl-G184S/fl-G184S}$ without Cre expression (Figure 6). Consistent with reduced myocardial infarct size (Figure 6), hearts isolated from tamoxifen-treated $Cre-ER^{T2}/G\alpha_{12}^{fl-G184S/fl-G184S}$ exhibited significantly enhanced postischemic recovery of developed pressure compared to hearts isolated from either vehicle-treated $Cre-ER^{T2}/G\alpha_{12}^{fl-G184S/fl-G184S}$ mice or tamoxifen-treated $G\alpha_{12}^{fl-G184S/fl-G184S}$ mice that do not express $Cre-ER^{T2}$ (Table 1). Postischemic recovery of +dP/dT and -dP/dT were also enhanced in hearts isolated from tamoxifen treated $Cre-ER^{T2}/G\alpha_{12}^{fl-G184S/fl-G184S}$ animals. Postischemic recovery of end diastolic pressure was nominally lower in tamoxifen-treated $Cre-ER^{T2}/G\alpha_{12}^{fl-G184S/fl-G184S}$ compared to the other groups (Table 1). However, this did not reach statistical significance. These data are consistent with our previous report that nonconditional expression of $G\alpha_{12}^{G184S}$ protects the heart from ischemic injury [13]. Importantly, they extend our previous findings by demonstrating that the cardioprotective phenotype does not result from embryonic or chronic expression of $G\alpha_{12}^{G184S}$. Rather, acute




disruption of interactions between $G\alpha_{i2}$ and endogenous RGS proteins is sufficient to induce cardioprotection.

Discussion

We previously described a mouse model in which signaling by $G\alpha_{i2}$ was enhanced by introduction of a point

mutation (G184S) that blocks negative regulation by RGS proteins [8]. These mice exhibited a number of complex and interesting phenotypes including protection from cardiac ischemia/reperfusion injury [13]. However, it was unclear whether this cardioprotective phenotype resulted from changes in $G\alpha_{i2}$ signaling during embryonic



development. It was also unknown whether chronic $G\alpha_{12}^{G184S}$ expression was required or whether acute expression was sufficient to protect the heart from ischemic injury. These are important issues because the potential finding that embryonic or chronic expression of $G\alpha_{12}^{G184S}$ is required for cardioprotection would likely preclude the use of pharmacological RGS inhibitors from therapeutic use in the treatment of ischemic heart disease. The present study extends our previous findings by demonstrating that acute (days rather than months) disruption of interactions between $G\alpha_{12}$ and endogenous RGS proteins is sufficient to protect the heart from ischemic injury. These data suggest that RGS proteins might provide novel therapeutic targets to protect the heart from ischemic injury.

Conditional expression of $G\alpha_{12}^{G184S}$ resulted in a 55% reduction in infarct size relative to hearts isolated from tamoxifen-treated mice that did not express $Cre-ER^{T2}$, and a 65% reduction in infarct size compared to hearts isolated from mice that expressed $Cre-ER^{T2}$ but were not treated with tamoxifen. By comparison, we previously

reported that nonconditional expression of $G\alpha_{12}^{G184S}$ resulted in 41% and 68% reductions in infarct sizes in hearts isolated from mice that were heterozygous or homozygous for the $G\alpha_{12}^{G184S}$ mutation, respectively [13]. Recovery of developed pressure, $+dP/dT$, and $-dP/dT$ were significantly increased in both models of $G\alpha_{12}^{G184S}$ expression (Table 1 and [13]). Thus, conditional expression of this mutation produced a cardioprotective phenotype that was similar to the phenotype previously observed in the conventional (nonconditional) $G\alpha_{12}^{G184S}$ knockin model.

Mice expressing the $G\alpha_{12}^{G184S}$ in a nonconditional fashion also exhibit several noncardiac phenotypic differences including: resistance to high fat diet-induced weight gain and resistance to the development of insulin insensitivity, reduced embryonic viability, elevated neutrophil counts, and antidepressant-like behavior [5,8,14]. We anticipate that the conditional $G\alpha_{12}^{G184S}$ expression model described here will be helpful in characterizing the temporal requirements (acute versus chronic) of $G\alpha_{12}^{G184S}$ expression for some of these phenotypes. Our finding that tamoxifen produced very little conversion to the $G\alpha_{12}^{G184S}$ mutation in the brain suggests that this model may not be useful for characterizing the anxiolytic or antidepressant-like behavior that has been previously reported in nonconditional $G\alpha_{12}^{G184S}$ mice [5]. On one hand, this represents a significant limitation of this model. However, the observation that the conventional $G\alpha_{12}^{G184S}$ model, but not the conditional $G\alpha_{12}^{G184S}$ model, expresses the G184S mutation in the brain might be useful for elucidating the ability of enhanced $G\alpha_{12}$ signaling in the central nervous system to impact the function of peripheral tissues. The reason for a lack of conversion to the $G\alpha_{12}^{G184S}$ mutation in the brain is unclear. However, other investigators using the $Cre-ER^{T2}$ system have reported similar results. Seibler et al. confirmed that $Cre-ER^{T2}$ is expressed in the brain and suggested that the lack of recombination may reflect low local concentrations of 4-hydroxytamoxifen [27].

The tamoxifen- and Cre-dependent recombination and expression of mutant mRNA meets the criteria planned for the engineered *Gnai2* locus: lack of mutant mRNA expression before tamoxifen treatment with good conversion to the G184S mutation after tamoxifen treatment. We did observe reduced $G\alpha_{12}$ protein expression in the heart, kidney, and brain of $G\alpha_{12}^{fl-G184S/fl-G184S}$ and $Cre-ER^{T2}/G\alpha_{12}^{fl-G184S/fl-G184S}$ mice relative to wildtype mice that do not express Cre or carry the G184S mutation, suggesting that the loss of introns in the minigene that carries the wildtype sequence and/or the residual LoxP or FLP recombinase (FRT) sites may perturb regulatory and/or splicing elements. However, the observation that LPA-induced inhibition of cAMP production is augmented in cardiac fibroblasts isolated from $Cre-ER^{T2}/G\alpha_{12}^{fl-G184S/fl-G184S}$ mice (Figure 5) indicates that




Figure 6 Conditional expression of $G\alpha_{12}^{G184S}$ protects the heart from ischemic injury. Conditional expression of $G\alpha_{12}^{G184S}$ significantly ($p < 0.001$) decreased infarct sizes in hearts exposed to 30 min of ischemia (A). Values represent means \pm SE. The number of replicates for each group is shown within the bars. Data were compared by one way ANOVA and posthoc Tukey analysis. *** indicates a significant difference ($p < 0.001$) compared to hearts isolated from tamoxifen treated $G\alpha_{12}^{fl-G184S}/fl-G184S$ mice, and ### indicates a significant difference ($p < 0.001$) compared to hearts isolated from $Cre-ERT^2/G\alpha_{12}^{fl-G184S}/fl-G184S$ mice that were treated with vehicle instead of tamoxifen. Photographs of representative triphenyltetrazolium chloride-stained hearts are shown in panel B.

Table 1 Preischemic and postischemic recovery of contractile function

	Preischemic			Postischemic recovery		
	Gα ₁₂ ^{fl-G184S/fl-G184S} + tamoxifen (n = 6)	Cre-ER ^{T2} /Gα ₁₂ ^{fl-G184S/fl-G184S} + tamoxifen (n = 6)	Cre-ER ^{T2} /Gα ₁₂ ^{fl-G184S/fl-G184S} + vehicle (n = 4)	Gα ₁₂ ^{fl-G184S/fl-G184S} + tamoxifen (n = 6)	Cre-ER ^{T2} /Gα ₁₂ ^{fl-G184S/fl-G184S} + tamoxifen (n = 6)	Cre-ER ^{T2} /Gα ₁₂ ^{fl-G184S/fl-G184S} + vehicle (n = 4)
Developed pressure (mmHg)	130 ± 6	140 ± 8	132 ± 6	45 ± 5	78 ± 8 * #	29 ± 7
+dP/dT (mmHg/sec)	6375 ± 570	6145 ± 621	4587 ± 251	2223 ± 321	3557 ± 521 #	985 ± 258
-dP/dT (mmHg/sec)	-4471 ± 291	-4601 ± 275	-3837 ± 235	-1600 ± 197	-2581 ± 263 * #	-908 ± 243
End diastolic pressure (mmHg)	5.7 ± 1.0	6.2 ± 0.9	5.0 ± 1.0	30 ± 2	21 ± 3	33 ± 7
Coronary flow rate (ml/min)	4.5 ± 0.4	4.1 ± 0.3	4.6 ± 0.4	2.7 ± 0.3	2.6 ± 0.2	2.9 ± 0.4

Preischemic contractile function was measured prior to 30 minutes of ischemia. Postischemic recovery of contractile function was measured following 1 hour of reperfusion. Data from each group were compared by one way ANOVA and posthoc Tukey analysis (preischemic and postischemic values were analyzed separately from one another). There were no significant differences between groups for any parameters of preischemic contractile function. *indicates a significant difference (p < 0.05) in postischemic recovery of contractile function compared to hearts isolated from tamoxifen treated Gα₁₂^{fl-G184S/fl-G184S} mice. # indicates a significant difference (p < 0.01) in postischemic recovery of contractile function compared to hearts isolated from Cre-ER^{T2}/Gα₁₂^{fl-G184S/fl-G184S} mice that were treated with vehicle instead of tamoxifen.

agonist-induced signaling via $G\alpha_{i2}$ is actually increased (relative to fibroblasts that do not express the mutation), despite decreased $G\alpha_{i2}$ expression levels. This presumably occurs because the negative regulatory effect of RGS proteins toward $G\alpha_{i2}$ is disrupted in these cells. Many different $G\alpha_i$ -coupled receptors are known to protect the heart from ischemia/reperfusion injury. Thus, the finding that conditional expression of $G\alpha_{i2}^{G184S}$ produces a cardioprotective phenotype is also consistent with enhanced $G\alpha_{i2}$ signaling despite decreased $G\alpha_{i2}$ protein expression.

Conclusions

In conclusion, the conditional $G\alpha_{i2}^{G184S}$ knock-in model described here permits the disruption of interactions between $G\alpha_{i2}$ and endogenous RGS proteins in a time-dependent manner. Our data demonstrate that acute (rather than chronic) disruption of interactions between RGS proteins and $G\alpha_{i2}$ is sufficient to protect the heart from ischemic injury. This suggests that the development of chemical inhibitors of RGS proteins or other agents that disrupt interactions between RGS proteins and $G\alpha_{i2}$ might provide new therapeutic tools to protect the heart from ischemic injury. In addition, we anticipate that this transgenic mouse model will provide a valuable tool for characterizing the mechanisms by which disruption of RGS protein- $G\alpha_{i2}$ interactions confers other phenotypes that have been identified in mice expressing $G\alpha_{i2}^{G184S}$.

Abbreviations

ACF: Adult cardiac fibroblast; ES: Embryonic stem; $G\alpha_{i2}^{+/+}$: Wildtype $G\alpha_{i2}$ allele; $G\alpha_{i2}^{G184S}$: $G\alpha_{i2}$ allele with point mutation; PCR: Polymerase chain reaction; RGS: Regulator of G protein signaling.

Competing interests

The authors have no financial or nonfinancial competing interests.

Authors' contributions

RRN, SP, and XH conceived and designed the experiments. SP, BRR, KK, RAC, SMW, and XH performed the experiments. SP, RRN, and BRR analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by NIH R01-GM39561 (RRN) and was also supported in part by the Michigan Diabetes, Research, and Training Center (NIH P60 DK20572), and the University of Michigan Comprehensive Cancer Center (NIH P30 CA046592). We thank Dr. Susanne Mumby (UT Southwestern Medical Center) for the specific $G\alpha_{i2}$ antibody, Dr. Thomas Gettys for the specific $G\alpha_{i1}$ and $G\alpha_{i3}$ antibodies, Dr. Thomas Saunders and Elizabeth Hughes (University of Michigan Transgenic Animal Model Core) for providing the FLPe mice and for the ES cells electroporation, respectively. We also thank Dr. Sally Camper, Dr. Thomas Saunders, and the staff at the University of Michigan Transgenic Animal Model Core and the staff at GenOway (Lyon, France) for helpful suggestions regarding the generation of the conditional knock-in mice.

Author details

¹Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109, USA. ²Department of Pharmaceutical and Biomedical Sciences, Ohio Northern University College of Pharmacy, Ada, OH 45810, USA. ³Department

of Pharmacology and Toxicology, B440 Life Sciences, Michigan State University, 1355 Bogue St, East Lansing, MI 48824, USA.

Received: 18 February 2014 Accepted: 28 May 2014
Published: 5 June 2014

References

- Hörnquist CE, Lu X, Rogers-Fani PM, Rudolph U, Shappell S, Birnbaumer L, Harriman GR: **G(alpha)12-deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1-type cytokines.** *J Immunol* 1997, **158**:1068–1077.
- DeGeorge BR Jr, Gao E, Boucher M, Vinge LE, Martini JS, Raake PW, Chuprun JK, Harris DM, Kim GW, Soltys S, Eckhart AD, Koch WJ: **Targeted inhibition of cardiomyocyte Gi signaling enhances susceptibility to apoptotic cell death in response to ischemic stress.** *Circulation* 2008, **117**:1378–1387.
- Nagata K, Ye C, Jain M, Milstone DS, Liao R, Mortensen RM: **Galpha(i2) but not Galpha(i3) is required for muscarinic inhibition of contractility and calcium currents in adult cardiomyocytes.** *Circ Res* 2000, **87**:903–909.
- Inoue Y, Yao L, Hopf FW, Fan P, Jiang Z, Bonci A, Diamond I: **Nicotine and ethanol activate protein kinase A synergistically via G(i) betagamma subunits in nucleus accumbens/ventral tegmental cocultures: the role of dopamine D(1)/D(2) and adenosine A(2A) receptors.** *J Pharmacol Exp Ther* 2007, **322**:23–29.
- Talbot JN, Jutkiewicz EM, Graves SM, Clemans CF, Nicol MR, Mortensen RM, Huang X, Neubig RR, Traynor JR: **RGS inhibition at G(alpha)12 selectively potentiates 5-HT1A-mediated antidepressant effects.** *Proc Natl Acad Sci U S A* 2010, **107**:11086–11091.
- Kimple AJ, Bosch DE, Giguere PM, Siderovski DP: **Regulators of G-protein signaling and their Galpha substrates: promises and challenges in their use as drug discovery targets.** *Pharmacol Rev* 2011, **2011**(63):728–749.
- Sjogren B, Blazer LL, Neubig RR: **Regulators of G protein signaling proteins as targets for drug discovery.** *Prog Mol Biol Transl Sci* 2010, **91**:81–119.
- Huang X, Fu Y, Charbeneau RA, Saunders TL, Taylor DK, Hankenson KD, Russell MW, D'Alecy LG, Neubig RR: **Pleiotropic phenotype of a genomic knock-in of an RGS-insensitive G184S Gna2 allele.** *Mol Cell Biol* 2006, **26**:6870–6879.
- Fu Y, Zhong H, Nanamori M, Mortensen RM, Huang X, Lan K, Neubig RR: **RGS-insensitive G-protein mutations to study the role of endogenous RGS proteins.** *Methods Enzymol* 2004, **389**:229–243.
- Fu Y, Huang X, Piao L, Lopatin AN, Neubig RR: **Endogenous RGS proteins modulate SA and AV nodal functions in isolated heart: implications for sick sinus syndrome and AV block.** *Am J Physiol Heart Circ Physiol* 2007, **292**:H2532–H2539.
- Fu Y, Huang X, Zhong H, Mortensen RM, D'Alecy LG, Neubig RR: **Endogenous RGS proteins and Galpha subtypes differentially control muscarinic and adenosine-mediated chronotropic effects.** *Circ Res* 2006, **98**:659–666.
- Kaur K, Parra S, Chen R, Charbeneau RA, Wade SM, Jay PY, Neubig RR: **Galpha(i2) signaling: friend or foe in cardiac injury and heart failure?** *Naunyn Schmiedeberg's Arch Pharmacol* 2012, **38**:443–453.
- Waterson RE, Thompson CG, Mabe NW, Kaur K, Talbot JN, Neubig RR, Rorabaugh BR: **Galpha(i2)-mediated protection from ischaemic injury is modulated by endogenous RGS proteins in the mouse heart.** *Cardiovasc Res* 2011, **91**:45–52.
- Huang X, Charbeneau RA, Fu Y, Kaur K, Gerin I, MacDougald OA, Neubig RR: **Resistance to diet-induced obesity and improved insulin sensitivity in mice with a regulator of G protein signaling-insensitive G184S Gna2 allele.** *Diabetes* 2008, **57**:77–85.
- Xin HB, Deng KY, Shui B, Qu S, Sun Q, Lee J, Greene KS, Wilson J, Yu Y, Feldman M, Kotlikoff M: **Gene trap and gene inversion methods for conditional gene inactivation in the mouse.** *Nucleic Acids Res* 2005, **33**:e14.
- Wingate AD, Martin KJ, Hunter C, Carr JM, Clacher C, Arthur JS: **Generation of a conditional CREB Ser133Ala knockin mouse.** *Genesis* 2009, **47**:688–696.
- Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, Warman ML: **Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT).** *Biotechniques* 2000, **29**:52–54.
- O'Connell TD, Rodrigo MC, Simpson PC (2007) **Isolation and culture of adult mouse cardiac myocytes.** *Methods Mol Biol* 2007, **357**:271–296.

19. Anastassiadis K, Glaser S, Kranz A, Berhardt K, Stewart AF: **A practical summary of site-specific recombination, conditional mutagenesis, and tamoxifen induction of CreERT2.** *Methods Enzymol* 2010, **2010**(477):109–123.
20. Hameyer D, Loonstra A, Eshkind L, Schmitt S, Antunes C, Groen A, Bindels E, Jonkers J, Krimpenfort P, Meuwissen R, Rijswijk L, Bex A, Berns A, Bockamp E: **Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues.** *Physiol Genomics* 2007, **31**:32–41.
21. Rodríguez CI, Buchholz F, Galloway J, Sequerra R, Kasper J, Ayala R, Stewart AF, Dymecki SM: **High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP.** *Nat Genet* 2000, **25**:139–140.
22. Strathmann M, Wilkie TM, Simon MI (1989) **Diversity of the G-protein family: sequences from five additional alpha subunits in the mouse.** *Proc Natl Acad Sci U S A* 1989, **86**:7407–7409.
23. Sullivan KA, Liao YC, Alborzi A, Beiderman B, Chang FH, Masters SB, Levinson AD, Bourne HR: **Inhibitory and stimulatory G proteins of adenylate cyclase: cDNA and amino acid sequences of the alpha chains.** *Proc Natl Acad Sci U S A* 1986, **83**:6687–6691.
24. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG: **Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.** *Blood* 2010, **115**:3589–3597.
25. Dizayee S, Kaestner S, Kuck F, Hein P, Klein C, Piekorz RP, Meszaros J, Matthes J, Nürnberg B, Herzig S: **Gai2- and Gai3-specific regulation of voltage-dependent L-type calcium channels in cardiomyocytes.** *PLoS One* 2011, **6**:e24979.
26. Foerster K, Groner F, Matthes J, Koch WJ, Birnbaumer L, Herzig S: **Cardioprotection specific for the G protein Gi2 in chronic adrenergic signaling through beta 2-adrenoceptors.** *Proc Natl Acad Sci U S A* 2003, **100**:14475–14480.
27. Seibler J, Zevnik B, Kuter-Luks B, Andreas S, Kern H, Hennek T, Rode A, Heimann C, Faust N, Kauselmann G, Schoor M, Jaenisch R, Rajewsky K, Kuhn R, Schwenk F: **Rapid generation of inducible mouse mutants.** *Nucleic Acids Res* 2003, **31**:e11–e13.

doi:10.1186/2050-6511-15-29

Cite this article as: Parra et al.: Conditional disruption of interactions between G α_{i2} and regulator of G protein signaling (RGS) proteins protects the heart from ischemic injury. *BMC Pharmacology and Toxicology* 2014 **15**:29.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

